http://www.biomedcentral.com/bmcwomenshealth//comments The latest comments on all articles published by BMC Women's Health 2013-04-03T13:40:10Z http://www.biomedcentral.com/1472-6874/13/12/comments#1425697 <p>Suggest rewording the title of this article which is not about 'eating competent low-income women'</p> Rhona O'Connll 2013-04-03T13:40:10Z http://www.biomedcentral.com/1472-6874/13/12 Lohse et al. BMC Women's Health 13 12 Wed Mar 13 00:00:00 GMT 2013 http://www.biomedcentral.com/1472-6874/9/28/comments#374663 <p>Great series very useful for patient information. <br/>It would be reassuring to know that the two deaths reported were not related to the tape procedure.</p> Shaun Fountain 2009-11-05T08:57:51Z http://www.biomedcentral.com/1472-6874/9/28 Kaelin-Gambirasio et al. BMC Women's Health 9 28 Fri Sep 25 14:32:03 BST 2009 http://www.biomedcentral.com/1472-6874/6/14/comments#366642 <p>Please note that the contact information for the first author has changed. New contact info: <br/> <br/>Noel N. Kim, PhD <br/>6330 Nancy Ridge Drive, Suite 102 <br/>San Diego, CA 92121 <br/> <br/>nnkim@alaginresearch.com <br/>noelkim@gmail.com</p> Noel Kim 2009-08-12T16:36:06Z http://www.biomedcentral.com/1472-6874/6/14 Kim et al. BMC Women's Health 6 14 Wed Sep 13 14:46:28 BST 2006 http://www.biomedcentral.com/1472-6874/4/5/comments#57455 <p>This paper prompted me to follow up the question of whether the patients in the studies reviewed were allowed to take the combined oral contraceptive pill. This is not mentioned as a specific exclusion criterion in the published papers. Dr Sahin (reference 13) was kind enough to confirm that pill users were indeed excluded. A response is not forthcoming so far from the corresponding author for reference 9.</p><p>Thus it seems to be a completely open question as to whether rofecoxib is effective for women using the combined oral contraceptive pill. This is rather extraordinary given that so many do use the pill in order to reduce dysmenorrhoea.</p><p>Two other points came up during my search of the Vioxx licensing documentation on the FDA website. Firstly, it is reassuring to note that rofecoxib had no effect on metabolism of the oral contraceptive pill- in contrast to valdecoxib which does seem to have some effect, albeit of uncertain clinical signficance. This is probably not so important in real life as pill users would typically be in their pill-free week while using analgesia for some days of the withdrawal bleed.</p><p>Secondly and more importantly, none of the studies have included participants under the age of 18. Thus we are at a loss as to how to advise younger women with dysmenorrhoea - who must represent at least a third of the population at risk of primary dysmenorrhoea- regarding rofecoxib.</p><p>One might wish that investigators would focus more closely on these important sub-groups of women with dysmenorrhoea, and not just do the 'easy' trials!</p> William Stones 2004-08-19T19:44:47Z http://www.biomedcentral.com/1472-6874/4/5 Edwards et al. BMC Women's Health 4 5 Tue Jul 20 00:00:00 BST 2004